We reach more than 65,000 registered users in Dec!! Register Now
Reclassification recommendations for drug in 'magic mushrooms': If phase III clinical trials are successful, researchers suggest categorizing the drug as schedule IV
- September 28, 2018
- 164 Views
- 0 Likes
- 0 Comment
In an evaluation of the safety and abuse research on the drug in hallucinogenic mushrooms, researchers suggest that if it clears phase III clinical trials, psilocybin should be re-categorized from a schedule I drug -- one with no known medical potential -- to a schedule IV drug such as prescription sleep aids, but with tighter control.
Cite This Article as
"Reclassification recommendations for drug in 'magic mushrooms': If phase III clinical trials are successful, researchers suggest categorizing the drug as schedule IV", MachPrinciple, September 28, 2018, https://machprinciple.com/post/Reclassification-recommendations-for-drug-in-magic-mushrooms-If-phase-III-clinical-trials-are-successful-researchers-suggest-categorizing-the-drug-as-schedule-IV
